Literature DB >> 12084213

A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferon.

Ken-Ryu Han, Allan J Pantuck, Arie S Belldegrun.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12084213     DOI： 10.1007/s11934-002-0004-9

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


× No keyword cloud information.
  6 in total

1.  Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.

Authors:  A Kugler; G Stuhler; P Walden; G Zöller; A Zobywalski; P Brossart; U Trefzer; S Ullrich; C A Müller; V Becker; A J Gross; B Hemmerlein; L Kanz; G A Müller; R H Ringert
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

2.  Renal cell carcinoma: recent progress and future directions.

Authors:  P Mulders; R Figlin; J B deKernion; R Wiltrout; M Linehan; D Parkinson; W deWolf; A Belldegrun
Journal:  Cancer Res       Date:  1997-11-15       Impact factor: 12.701

3.  Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.

Authors:  S Negrier; B Escudier; C Lasset; J Y Douillard; J Savary; C Chevreau; A Ravaud; A Mercatello; J Peny; M Mousseau; T Philip; T Tursz
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

Review 4.  Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment.

Authors:  S S Taneja; W Pierce; R Figlin; A Belldegrun
Journal:  Urology       Date:  1995-06       Impact factor: 2.649

5.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

Authors:  R Childs; A Chernoff; N Contentin; E Bahceci; D Schrump; S Leitman; E J Read; J Tisdale; C Dunbar; W M Linehan; N S Young; A J Barrett
Journal:  N Engl J Med       Date:  2000-09-14       Impact factor: 91.245

Review 6.  Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

Authors:  J P Dutcher; M Atkins; R Fisher; G Weiss; K Margolin; F Aronson; J Sosman; M Lotze; M Gordon; T Logan; J Mier
Journal:  Cancer J Sci Am       Date:  1997-12
  6 in total
  1 in total

Review 1.  Emerging molecular classification in renal cell carcinoma: implications for drug development.

Authors:  Kathryn E Hacker; W Kimryn Rathmell
Journal:  Target Oncol       Date:  2010-07-20       Impact factor: 4.493
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.